Climb Bio Reports Early Phase 1 Data for IgA Nephropathy Drug

MT Newswires Live09-03 19:54

Climb Bio (CLYM) said Thursday its phase 1 trial data for its experimental antibody treatment CLYM116 demonstrated a 29-day half-life that supports dosing every 12 weeks for patients with IgA nephropathy.

A single 320-milligram dose achieved nearly complete protein suppression and lowered specific antibody levels by 60% to 75% over a 12-week period, the company said.

The kidney disease drug candidate was generally well-tolerated without any serious adverse events or dose-limiting toxicities, it said.

The company plans to release initial findings from an ongoing phase 2 trial during H1 of 2027, and to start a phase 3 study in 2027, Climb Bio said.

Shares of the company were up 7% in Thursday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664871981?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664871981","market":"nz","top_or_hot":-1,"title":"Climb Bio Reports Early Phase 1 Data for IgA Nephropathy Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a> (CLYM) said Thursday its phase 1 trial data for its experimental antibody treatment CLYM116 demonstrated a 29-day half-life that supports dosing every 12 weeks for patients with IgA nephropathy.</p><p>A single 320-milligram dose achieved nearly complete protein suppression and lowered specific antibody levels by 60% to 75% over a 12-week period, the company said.</p><p>The kidney disease drug candidate was generally well-tolerated without any serious adverse events or dose-limiting toxicities, it said.</p><p>The company plans to release initial findings from an ongoing phase 2 trial during H1 of 2027, and to start a phase 3 study in 2027, Climb Bio said.</p><p>Shares of the company were up 7% in Thursday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio Reports Early Phase 1 Data for IgA Nephropathy Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio Reports Early Phase 1 Data for IgA Nephropathy Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-03 19:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a> (CLYM) said Thursday its phase 1 trial data for its experimental antibody treatment CLYM116 demonstrated a 29-day half-life that supports dosing every 12 weeks for patients with IgA nephropathy.</p><p>A single 320-milligram dose achieved nearly complete protein suppression and lowered specific antibody levels by 60% to 75% over a 12-week period, the company said.</p><p>The kidney disease drug candidate was generally well-tolerated without any serious adverse events or dose-limiting toxicities, it said.</p><p>The company plans to release initial findings from an ongoing phase 2 trial during H1 of 2027, and to start a phase 3 study in 2027, Climb Bio said.</p><p>Shares of the company were up 7% in Thursday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLYM","symbol_name":"CLIMB BIO INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664871981","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664871981","pubTimestamp":1788436486,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Climb Bio  said Thursday its phase 1 trial data for its experimental antibody treatment CLYM116 demonstrated a 29-day half-life that supports dosing every 12 weeks for patients with IgA nephropathy.A single 320-milligram dose achieved nearly complete protein suppression and lowered specific antibody levels by 60% to 75% over a 12-week period, the company said.The kidney disease drug candidate was generally well-tolerated without any serious adverse events or dose-limiting toxicities, it said.The company plans to release initial findings from an ongoing phase 2 trial during H1 of 2027, and to start a phase 3 study in 2027, Climb Bio said.Shares of the company were up 7% in Thursday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLYM":"CLIMB BIO INC","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Climb Bio 报告 IgA 肾病药物的早期 1 期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":1},"content_text":"Climb Bio (CLYM) said Thursday its phase 1 trial data for its experimental antibody treatment CLYM116 demonstrated a 29-day half-life that supports dosing every 12 weeks for patients with IgA nephropathy.A single 320-milligram dose achieved nearly complete protein suppression and lowered specific antibody levels by 60% to 75% over a 12-week period, the company said.The kidney disease drug candidate was generally well-tolerated without any serious adverse events or dose-limiting toxicities, it said.The company plans to release initial findings from an ongoing phase 2 trial during H1 of 2027, and to start a phase 3 study in 2027, Climb Bio said.Shares of the company were up 7% in Thursday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664871981","isCrawlerRequest":true}